Peptide Atlas · Peptide

Pemvidutide

Pemvidutide is a GLP-1 and glucagon dual receptor agonist; in a 12-week randomized trial in 94 people with metabolic dysfunction-associated steatotic liver disease, weekly injections cut liver fat by 46.6% to 68.5% from baseline against 4.4% on placebo.

emerging

provisional
1 citation
0 discussions
0 followers
ALT-801

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

created page created as 'Pemvidutide' with aliases ALT-801 · 2026-09-27 12:04 · somebody
kind set kind set to peptide: palette r2 · 2026-09-27 12:04 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 12:04 · somebody
fact added summary: Pemvidutide is a GLP-1 and glucagon dual receptor agonist; in a 12-week randomized trial in 94 people with metabolic dys · 2026-09-27 12:04 · somebody
citation added pmid 39002641 cited as emerging: Pemvidutide reduced liver fat content over 12 weeks in MASLD (RCT, n=94) · 2026-09-27 12:04 · somebody

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.